KR20130028807A - 방사선 유발성 장염의 예방, 치료 및 개선 방법 - Google Patents

방사선 유발성 장염의 예방, 치료 및 개선 방법 Download PDF

Info

Publication number
KR20130028807A
KR20130028807A KR1020137005518A KR20137005518A KR20130028807A KR 20130028807 A KR20130028807 A KR 20130028807A KR 1020137005518 A KR1020137005518 A KR 1020137005518A KR 20137005518 A KR20137005518 A KR 20137005518A KR 20130028807 A KR20130028807 A KR 20130028807A
Authority
KR
South Korea
Prior art keywords
cancer
valsalazide
administered
patient
radiation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020137005518A
Other languages
English (en)
Korean (ko)
Inventor
더그 베텐하우젠
크리스토퍼 야러스
Original Assignee
샐릭스 파마슈티컬스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 샐릭스 파마슈티컬스 인코포레이티드 filed Critical 샐릭스 파마슈티컬스 인코포레이티드
Priority claimed from PCT/US2005/018757 external-priority patent/WO2005117851A1/en
Publication of KR20130028807A publication Critical patent/KR20130028807A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020137005518A 2004-05-28 2005-05-27 방사선 유발성 장염의 예방, 치료 및 개선 방법 Ceased KR20130028807A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60895104P 2004-05-28 2004-05-28
US60/608,951 2004-10-26
PCT/US2005/018757 WO2005117851A1 (en) 2004-05-28 2005-05-27 Prevention, treatment, and amelioration of radiation induced enteritis

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020117025133A Division KR20110121730A (ko) 2004-05-28 2005-05-27 방사선 유발성 장염의 예방, 치료 및 개선 방법

Publications (1)

Publication Number Publication Date
KR20130028807A true KR20130028807A (ko) 2013-03-19

Family

ID=40096437

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020137005518A Ceased KR20130028807A (ko) 2004-05-28 2005-05-27 방사선 유발성 장염의 예방, 치료 및 개선 방법

Country Status (4)

Country Link
US (3) US20080306029A1 (enExample)
JP (1) JP5009152B2 (enExample)
KR (1) KR20130028807A (enExample)
DE (1) DE602005022175D1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012021031A (ja) * 2004-10-26 2012-02-02 Salix Pharmaceuticals Inc 放射線誘発性腸炎の予防、処置、および回復
RU2618452C1 (ru) * 2015-12-28 2017-05-03 Федеральное государственное бюджетное образовательное учреждение высшего образования "Астраханский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Астраханский ГМУ Минздрава России) Способ прогнозирования энтерита
CA3259788A1 (en) * 2022-06-22 2023-12-28 Marjan BOERMA METHOD FOR ATTENUATING INJURY BY RADIATION USING GERANYL TRANSFERASE INHIBITORS
CN115252685A (zh) * 2022-06-24 2022-11-01 内蒙古民族大学附属医院 一种蒙药巴特日-7在预防和治疗放射性肠道损伤中的应用

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE791889A (fr) * 1971-11-26 1973-05-24 Pharmacia Ab Nouveaux derives de la pyridine
US4298595A (en) * 1978-12-20 1981-11-03 Dynapol Pharmaceutical preparations containing a polymeric agent for releasing 5-aminosalicylic acid or its salts into the gastrointestinal tract
US4960765A (en) * 1980-03-20 1990-10-02 Farmaceutisk Laboratorium Ferring A/S Pharmaceutical composition and method for the treatment of colitis ulcerosa and Crohn's disease by oral administration
WO1981002671A1 (en) * 1980-03-20 1981-10-01 Ferring Farma Lab Pharmaceutical composition and method for the treatment of colitis ulcerosa and crohn's disease by oral administration
EP0039306B1 (de) * 1980-03-28 1984-01-11 Ciba-Geigy Ag Neue Azofarbstoffe, Verfahren zu deren Herstellung und deren Verwendung
US4412922A (en) * 1980-07-02 1983-11-01 Abcor, Inc. Positive-charged ultrafiltration membrane for the separation of cathodic/electrodeposition-paint compositions
US4412992A (en) * 1980-07-21 1983-11-01 Biorex Laboratories Limited 2-Hydroxy-5-phenylazobenzoic acid derivatives and method of treating ulcerative colitis therewith
ZA825384B (en) * 1981-07-31 1983-05-25 Tillott J B Ltd Orally administrable pharmaceutical compositions
US4562024A (en) * 1982-07-06 1985-12-31 Sterling Drug Inc. Process for preparing granulate containing poorly compressible medicinally active matter
SE8405924L (sv) * 1984-11-23 1986-05-24 Pharmacia Ab Nya azoforeningar
US4781925A (en) * 1986-03-06 1988-11-01 American Home Products Corporation Calcium supplement compressed tablets
US5374430A (en) * 1986-09-18 1994-12-20 London School Of Pharmacy Pharmaceutical formulation
EP0439453B1 (en) * 1987-10-12 1994-01-19 Exomed Australia Pty. Ltd. (ACN 051 976 446) Improved method for treatment of gastrointestinal disorders
US5064637A (en) * 1989-05-30 1991-11-12 Board Of Regents, The University Of Texas System Substituted sulfonamide derivatives which inhibit allergic reactions
US5095073A (en) * 1990-03-02 1992-03-10 Exxon Research And Engineering Company Water soluble rigid rod sulfonated aromatic polyamide
US5519014A (en) * 1990-10-22 1996-05-21 Borody; Thomas J. Treatment of non-inflammatory and non-infectious bowel disorders
ES2111659T3 (es) * 1992-03-11 1998-03-16 Asta Medica Ag Comprimidos, granulados y nodulos con alto contenido en sustancias activas para formas de administracion solidas de alta concentracion.
US5498608A (en) * 1994-01-07 1996-03-12 Salix Pharmaceuticals Use of 2-hydroxy-5-phenylazobenzoic acid derivatives as colon cancer chemopreventative and chemotherapeutic agents
US6562629B1 (en) * 1999-08-11 2003-05-13 Cedars-Sinai Medical Center Method of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth by detecting the presence of anti-saccharomyces cerivisiae antibodies (asca) in human serum
US6231888B1 (en) * 1996-01-18 2001-05-15 Perio Products Ltd. Local delivery of non steroidal anti inflammatory drugs (NSAIDS) to the colon as a treatment for colonic polyps
SE9700934D0 (sv) * 1997-03-14 1997-03-14 Astra Ab New formulation
DE69839261T2 (de) * 1997-04-01 2009-03-26 Borody, Thomas Julius, Five Dock Verfahren und zusammensetzungen zur behandlung entzündlicher darmerkrankungen
US6551632B2 (en) * 1997-04-01 2003-04-22 Thomas Julius Borody Methods and compositions for treating inflammatory bowel disease
US20030078205A1 (en) * 2001-07-31 2003-04-24 Podolsky Daniel K. Methods and compositions for treating and preventing distal bowel lesions
AUPO665397A0 (en) * 1997-05-07 1997-05-29 Borody, Thomas Julius Novel therapy for constipation
US6144381A (en) * 1997-05-14 2000-11-07 International Business Machines Corporation Systems, methods and computer program products for compass navigation of avatars in three dimensional worlds
DE19732903A1 (de) * 1997-07-30 1999-02-04 Falk Pharma Gmbh Pellet-Formulierung zur Behandlung des Intestinaltraktes
US5927500A (en) * 1998-06-09 1999-07-27 Milliken & Company Pharmaceutical containment package
AUPP437698A0 (en) * 1998-06-30 1998-07-23 Baumgart, Karl Methods for treatment of coronary, carotid and other vascular disease
US6517871B1 (en) * 1998-07-20 2003-02-11 Smithkline Beecham Corporation Bioenhanced formulations comprising eprosartan in oral solid dosage form
US6326364B1 (en) * 1999-02-08 2001-12-04 Cedars-Sinai Medical Center Use of 5-aminosalicylates as antimicrobial agents
US20030138399A1 (en) * 1999-05-14 2003-07-24 Anton Peter A. Anti-inflammatory therapy for inflammatory mediated infection
DE60115465T2 (de) * 2000-08-29 2006-08-03 Nobex Corp. Immunoregulierende verbindungen, deren derivate und ihre verwendung
EP1313699B1 (en) * 2000-08-29 2010-03-10 Biocon Limited 5-asa derivatives having anti-inflammatory and antibiotic activity and methods of treating diseases therewith
US6562871B1 (en) * 2000-11-06 2003-05-13 Boehringer Ingelheim Pharmaceuticals, Inc. Dry granulation of pharmaceutical formulation comprising mexiletine
CA2359812C (en) * 2000-11-20 2004-02-10 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
US6407128B1 (en) * 2001-12-03 2002-06-18 Elan Pharmaceuticals, Inc. Method for increasing the bioavailability of metaxalone
AU2003226752A1 (en) * 2002-03-28 2003-10-13 Synthon B.V. Venlafaxine base
JPWO2004082715A1 (ja) * 2003-03-20 2006-06-22 エーザイ株式会社 炎症性腸疾患治療剤としての併用医薬
US7825106B2 (en) * 2003-09-03 2010-11-02 Agi Therapeutics Ltd. Modified release formulations and methods of treating inflammatory bowel disease
US7737133B2 (en) * 2003-09-03 2010-06-15 Agi Therapeutics Ltd. Formulations and methods of treating inflammatory bowel disease
US7452872B2 (en) * 2005-08-24 2008-11-18 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
EP2529729A1 (en) * 2005-08-24 2012-12-05 Salix Pharmaceuticals, Inc. Balsalazide formulations and manufacture thereof
US20100048519A1 (en) * 2006-09-13 2010-02-25 Chyon-Hwa Yeh Methods of treatment for ulcerative colitis using aminosalicylate

Also Published As

Publication number Publication date
US20160120886A1 (en) 2016-05-05
US20170333458A1 (en) 2017-11-23
DE602005022175D1 (de) 2010-08-19
HK1099517A1 (en) 2007-08-17
JP5009152B2 (ja) 2012-08-22
JP2008517871A (ja) 2008-05-29
US20080306029A1 (en) 2008-12-11

Similar Documents

Publication Publication Date Title
Laval et al. The use of steroids in the management of inoperable intestinal obstruction in terminal cancer patients: do they remove the obstruction?
WO2016062283A1 (zh) 抗发炎用药物在制备抑制癌症的医药组合物中的应用
US20170333458A1 (en) Prevention, treatment, and amelioration of radiation induced enteritis
Scarabelli et al. Intermittent pelvic arterial infusion with peptichemio, doxorubicin, and cisplatin for locally advanced and recurrent carcinoma of the uterine cervix
RU2011151854A (ru) Новые терапевтические способы применения инекальцитола
KR101386601B1 (ko) 방사선 유발성 장염의 예방, 치료 및 개선 방법
TWI670056B (zh) 二甲雙胍與丁酸鈉於治療慢性發炎造成之病狀的用途
WO2013190273A1 (en) Therapeutic composition
AU683145B2 (en) Methods for treating neurofibromatosis
CN102225101B (zh) 一种治疗痔疮的中药
KR20210048801A (ko) 설글리코타이드를 유효성분으로 포함하는 염증성 장질환의 예방 또는 치료용 조성물
HK1099517B (en) Prevention, treatment, and amelioration of radiation induced enteritis
CN117898996A (zh) 一种治疗痔疮的栓剂及其制备方法
Al-Mosawi The treatment of childhood progressive bilateral multiple renal stone disease: A role of essential oil terpenes
AU2011213847A1 (en) Prevention, treatment, and amelioration of radiation induced enteritis
JP2012021031A (ja) 放射線誘発性腸炎の予防、処置、および回復
ES2348039T3 (es) Prevencion, tratamiento y mejora de la enteritis inducida por radiacion.
Gopal et al. Delayed-onset lumbosacral polyradiculitis following proton precision beam therapy for localized prostate cancer: A case report
RU2147896C1 (ru) Способ лечения ограниченной склеродермии
Bennett et al. Treatment of chronic craniofacial pain with Mphi laser and orthotic
Teelucksingh et al. Use of radioiodine in adolescent Graves' disease
CN117243948A (zh) 包含瑞香素的组合物在制备风湿性关节炎药物中的应用
Das et al. Clinical researches carried out on mootrashmari at Jamnagar
Busutti Clinical trials and preliminary results obtained by association of electroaffinic hypoxic cell radiosensitizing drugs (misonidazole and metronidazole) with radiotherapy (telecobalt therapy) for the treatment of some types of neoplastic diseases at a locally advanced stage
Miller et al. Management of methoxsalen-induced nausea with metoclopramide

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20130304

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20130403

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20130605

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20140701

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20130605

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I